Comparing Mavenclad vs Tysabri
| Mavenclad (cladribine) | Tysabri (natalizumab) |
|
|---|
| Mavenclad (cladribine) | Tysabri (natalizumab) |
|
|||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Mavenclad may be given to people with relapsing forms of MS who have had an inadequate response to, or who are unable to tolerate other medications for MS that have a more favorable safety profile... View more |
Prescription only
Tysabri may be used to treat adults with multiple sclerosis or Crohn's disease and is given once every four weeks through an infusion center registered with the Touch Prescribing Program. A headache... View more |
Related suggestions Popular comparisons
|
|||||||||||||||
| More about Mavenclad (cladribine) | More about Tysabri (natalizumab) | ||||||||||||||||
| Ratings & Reviews | |||||||||||||||||
|
Mavenclad has an average rating of 8.8 out of 10 from a total of 4 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
Tysabri has an average rating of 7.7 out of 10 from a total of 98 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 15% reported a negative effect. |
||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | |||||||||||||||||
|
View all Mavenclad side effects |
View all Tysabri side effects |
||||||||||||||||
| Drug Class | |||||||||||||||||
| Generic Availability | |||||||||||||||||
|
N/A |
|||||||||||||||||
| Pricing and Coupons * Prices are without insurance | |||||||||||||||||
View all Mavenclad prices |
View all Tysabri prices |
||||||||||||||||
| Dosage Forms | |||||||||||||||||
|
|
||||||||||||||||
| Brand Names | |||||||||||||||||
| Other cladribine brands include: Cladribine Novaplus | Other natalizumab brands include: Tyruko | ||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | |||||||||||||||||
|
6.7 hours |
360 hours |
||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | |||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||
| Pregnancy Category | |||||||||||||||||
|
Category D
Positive evidence of risk
See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
||||||||||||||||
| Drug Interactions | |||||||||||||||||
|
A total of 497 drugs are known to interact with Mavenclad:
|
A total of 414 drugs are known to interact with Tysabri:
|
||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | |||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||
| Disease Interactions | |||||||||||||||||
| First Approval Date | |||||||||||||||||
|
March 29, 2019 |
November 23, 2004 |
||||||||||||||||
| WADA Class View classifications | |||||||||||||||||
|
N/A |
N/A |
||||||||||||||||
| More Information | |||||||||||||||||
| Patient Resources | |||||||||||||||||
| Professional Resources | |||||||||||||||||
| Related Treatment Guide | |||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.